Delfi
DELFI Diagnostics is developing next-generation, blood-based tests that are convenient, accessible, and reliable, offering a new way to help detect cancer. DELFI's proprietary technology leverages advanced AI to analyze patterns of circulating cell-free DNA fragments in the blood, an approach known as fragmentomics, to help detect lung cancer with high sensitivity. FirstLook Lung, the first commer
Palo Alto, CA, USA200 people
1 of 8 roles
All teams8Assay Research & Development2Lab Operations3Software Engineering & IT1Market Access1Clinical Development1
Roles are read from Delfi’s Lever every hour and disappear here as soon as they close there.